EUCTR2009-010955-29-NL进行中（未招募）不适用
Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
Division of Clinically Immunology and Rheumatology, AMC0 个研究点开始时间: 2009年2月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with pre-clinical RA, defined by the presence of arthralgia and at least one of the following features:
- •¦ IgM-rheumatoid factor (IgM-RF) of > 12.5 IU/ml
- •¦anti-citrullinated peptide antibodies (ACPA) in the serum of > 25 IU/ml
- •and at least one of the following features:
- •¦CRP > 3 mg/l
- •¦ESR > 28 mm/h
- •¦Subclinical synovitis as assessed by ultrasound
- •¦Subclinical synovitis as assessed by MRI
- •- Age 18-80 years
- •- Patients of reproductive potential (males and females) must use a reliable means of contraception (e.g. contraceptive pill, IUD, physical barrier) until one year after the last infusion of rituximab or the entire duration that the patient is B-cell depleted, whichever is longer.
- •- Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Clinically evident arthritis, as assessed by a rheumatologist and/or a research physician.
- •- History of arthritis, as assessed by a rheumatologist.
- •- History or current use of DMARDs or biologicals
- •- Previous treatment with any cell depleting therapies, including investigational agents (e.g. CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19)
- •- Presence of any disease for which patient needs chronic or intermittent immunosuppressive therapy (e.g. prednisolon for COPD)
- •- Previous treatment within 6 months with intravenous gamma globulin
- •- History of (oral or) parenteral corticosteroid use within 4 weeks prior to inclusion
- •- Receipt of a live vaccine within 4 weeks prior to randomization
- •- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- •- Significant cardiac or pulmonary disease (including obstructive pulmonary disease)
- •- Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders
- •- Known active bacterial, viral, fungal, mycobacterial or other infection (including tuberculosis, or atypical mycobacterial disease, but excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
- •- History of recurrent significant infection or history of recurrent bacterial infections
- •- Primary or secondary immunodeficiency (history of, or currently active)
- •- History of cancer, including solid tumors and hematologic malignancies (except basal cell or squamous cell carcinoma of the skin that has been excised and cured)
- •- Pregnant women or nursing (breast feeding) mothers
- •- History of alcohol, drug or chemical abuse within 6 months prior to screening
- •- Patients with poor peripheral venous access
- •- AST or ALT > 2.5 times upper limit of normal
- •- Platelet count less than 100 x 109/l
- •- A white cell count less than 3.5 x 109/l
- •- Hemoglobin of less than 5.3 mmol/l
- •- Positive tests for hepatitis B surface antigen or hepatitis C antibody or HIV
- •- Levels of IgG and/or IgM below 5.65 and 0.55 mg/mL respectively
研究者
相似试验
尚未招募
不适用
Prevention of RA by B cell directed therapy.pre-clinical RANL-OMON28176Academic Medical Center/University of Amsterdam, Amsterdam90
已完成
不适用
Primary prevention of rheumatoid arthritisMusculoskeletal DiseasesRheumatoid arthritisISRCTN73232918Jan van Breemen Instituut (Netherlands)80
已完成
不适用
Active management of rheumatoid arthritis (RA)ISRCTN78142229Record Provided by the NHSTCT Register - 2004 Update - Department of Health (UK)100
已完成
不适用
Prevention of cartilage destruction in rheumatoid arthritis by etanercept (PRECEPT study)Rheumatoid arthritisJPRN-UMIN000001798Team RA, Rheumatosurgery, Osaka City University Medical School100
招募中
不适用
Korean nation-wide prospective multicenter cohort for rheumatoid arthritisDiseases of the musculo-skeletal system and connective tissueKCT0000086Hanyang University3,000